Qiang Zhao
Direktor/Vorstandsmitglied bei Shanghai Haihe Biopharma Co., Ltd.
Aktive Positionen von Qiang Zhao
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Shanghai Haihe Biopharma Co., Ltd.
 Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | Direktor/Vorstandsmitglied | 08.09.2020 | - |
| Independent Dir/Board Member | 08.09.2020 | - |
Karriereverlauf von Qiang Zhao
Ehemalige bekannte Positionen von Qiang Zhao
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD. | Direktor/Vorstandsmitglied | 26.05.2017 | 10.06.2023 |
| Independent Dir/Board Member | 26.05.2017 | 10.06.2023 | |
| JOINTO ENERGY INVESTMENT CO., LTD. HEBEI | Direktor/Vorstandsmitglied | 12.09.2014 | - |
| Independent Dir/Board Member | 12.09.2014 | - |
Statistik
International
| China | 4 |
Operativ
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
Sektoral
| Utilities | 2 |
| Producer Manufacturing | 2 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| JOINTO ENERGY INVESTMENT CO., LTD. HEBEI | Utilities |
| BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD. | Producer Manufacturing |
| Private Unternehmen | 1 |
|---|---|
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | Commercial Services |
- Börse
- Insiders
- Qiang Zhao
- Erfahrung
